CBD Life Sciences, Inc. (CBDL) Announces Strategic MOU With U.S. Armed Forces for Groundbreaking Mushroom Supplement
CBD Life Sciences (OTC PINK:CBDL) has signed a Memorandum of Understanding (MOU) with a division of the United States Armed Forces, potentially positioning the company for significant growth in the $14.6 billion adaptogens market. CBDL's mushroom supplement drink powder, featuring reishi mushroom, lion's mane, and ashwagandha root extract, aims to optimize mental clarity, physical stamina, and recovery.
The company has already achieved a 1405.46% revenue increase since February 2024. This MOU opens doors to a massive, untapped market for CBDL's nutraceutical solutions. CEO Lisa Nelson emphasized the partnership's potential as a game-changer for the company. The agreement is expected to serve as a major growth catalyst, driving revenue and elevating the brand into new, high-profile markets.
CBD Life Sciences (OTC PINK:CBDL) ha firmato un Memorandum of Understanding (MOU) con una divisione delle Forze Armate degli Stati Uniti, posizionando potenzialmente l'azienda per una crescita significativa nel mercato degli adattogeni da 14,6 miliardi di dollari. La bevanda in polvere di integratore a base di funghi di CBDL, che presenta funghi reishi, criniera di leone e estratto di radice di ashwagandha, mira a ottimizzare la chiarezza mentale, la resistenza fisica e il recupero.
L'azienda ha già registrato un incremento del fatturato del 1405,46% dal febbraio 2024. Questo MOU apre porte a un enorme mercato inesplorato per le soluzioni nutraceutiche di CBDL. La CEO Lisa Nelson ha sottolineato il potenziale della partnership come un cambiamento di gioco per l'azienda. L'accordo dovrebbe fungere da importante catalizzatore di crescita, aumentando il fatturato e portando il marchio in nuovi mercati di alto profilo.
CBD Life Sciences (OTC PINK:CBDL) ha firmado un Memorando de Entendimiento (MOU) con una división de las Fuerzas Armadas de los Estados Unidos, posicionando potencialmente a la empresa para un crecimiento significativo en el mercado de adaptógenos de 14.6 mil millones de dólares. El polvo de bebida de suplemento de hongos de CBDL, que cuenta con hongo reishi, melena de león y extracto de raíz de ashwagandha, tiene como objetivo optimizar la claridad mental, la resistencia física y la recuperación.
La empresa ya ha logrado un aumento de ingresos del 1405.46% desde febrero de 2024. Este MOU abre puertas a un enorme mercado no explotado para las soluciones nutracéuticas de CBDL. La CEO Lisa Nelson enfatizó el potencial de la asociación como un cambio de juego para la empresa. Se espera que el acuerdo sirva como un importante catalizador de crecimiento, impulsando los ingresos y elevando la marca a nuevos mercados de alto perfil.
CBD 라이프 사이언스 (OTC PINK:CBDL)는 미국 군대의 한 부서와 이해각서 (MOU)를 체결하여, 회사가 146억 달러의 적응제 시장에서 큰 성장을 이룰 수 있는 위치에 잠재적으로 놓이게 되었습니다. CBDL의 버섯 보충제 음료 분말은 영지버섯, 사자의 갈기, 아슈와간다 뿌리 추출물을 포함하고 있으며, 정신적 명료성, 신체 지구력 및 회복을 최적화하는 것을 목표로 합니다.
이 회사는 이미 2024년 2월 이후 1405.46%의 수익 증가를 달성했습니다. 이 MOU는 CBDL의 건강기능식품 솔루션을 위한 엄청난 미개척 시장으로의 길을 열어줍니다. CEO 리사 넬슨은 이 파트너십의 잠재력을 회사의 게임 체인저로 강조했습니다. 이 계약은 주요 성장 촉매 역할을 하여 수익을 증대시키고 브랜드를 새로운 고급 시장으로 끌어올릴 것으로 기대됩니다.
CBD Life Sciences (OTC PINK:CBDL) a signé un Mémorandum d'Entente (MOU) avec une division des Forces Armées des États-Unis, positionnant potentiellement l'entreprise pour une croissance significative sur le marché des adaptogènes de 14,6 milliards de dollars. La poudre de boisson complémentaire à base de champignons de CBDL, comprenant des champignons reishi, une crinière de lion et de l'extrait de racine d'ashwagandha, vise à optimiser la clarté mentale, l'endurance physique et la récupération.
L'entreprise a déjà enregistré une augmentation de revenus de 1405,46% depuis février 2024. Ce MOU ouvre des portes à un vaste marché inexploité pour les solutions nutraceutiques de CBDL. La PDG Lisa Nelson a souligné le potentiel de ce partenariat comme un changement de donne pour l'entreprise. L'accord devrait servir de catalyseur majeur de croissance, stimulant les revenus et élevant la marque vers de nouveaux marchés de haut niveau.
CBD Life Sciences (OTC PINK:CBDL) hat ein Memorandum of Understanding (MOU) mit einer Division der US-Streitkräfte unterzeichnet, was potenziell das Unternehmen für signifikantes Wachstum im 14,6 Milliarden Dollar schweren Adaptogenmarkt positioniert. Das Pilzergänzungsmittel-Pulver von CBDL, das Reishi-Pilz, Löwenmähne und Ashwagandha-Wurzelextrakt enthält, zielt darauf ab, die geistige Klarheit, körperliche Ausdauer und Erholung zu optimieren.
Das Unternehmen hat bereits seit Februar 2024 einen Umsatzanstieg von 1405,46% erzielt. Dieses MOU öffnet Türen zu einem riesigen, ungenutzten Markt für die nutraceutical Lösungen von CBDL. CEO Lisa Nelson betonte das Potenzial dieser Partnerschaft als Wendepunkt für das Unternehmen. Es wird erwartet, dass die Vereinbarung als wesentlicher Wachstumskatalysator fungiert, die Einnahmen steigert und die Marke in neue, hochkarätige Märkte hebt.
- Signed MOU with a division of the U.S. Armed Forces, potentially opening a large new market
- 1405.46% revenue increase since February 2024
- Positioned to capture significant market share in the $14.6 billion adaptogens market
- Expanding product line and strategic partnerships
- None.
CBD Life Sciences propels its expansion with a major MOU, positioning the company for multi-million-dollar growth in the booming
SCOTTSDALE, AZ / ACCESSWIRE / October 15, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL) is excited to announce the signing of a game-changing Memorandum of Understanding (MOU) with a division of the United States Armed Forces, marking a pivotal moment in the company's journey toward revolutionizing health and performance solutions. While the details of the agreement are confidential, this partnership could position CBDL at the forefront of high-performance health solutions, creating a massive opportunity for growth and expansion in the nutraceuticals market.
CBD Life Sciences' mushroom supplement drink powder, featuring a powerful combination of reishi mushroom, lion's mane, and ashwagandha root extract, is crafted to optimize mental clarity, physical stamina, and recovery. This all-natural formula delivers stress relief, cognitive enhancement, and immune system support-qualities highly sought after in both the civilian and military sectors, especially for individuals operating in high-stress, demanding environments.
With the U.S. Armed Forces expressing interest in the company's innovative supplement, CBD Life Sciences is positioned to redefine how performance and health are approached, not only by elite personnel but by health-conscious consumers around the globe. This MOU opens a strategic door into a massive, untapped market for the company's rapidly growing portfolio of nutraceutical solutions.
Massive Growth, Unlimited Potential
CBD Life Sciences is no stranger to explosive growth, having already achieved a staggering
CEO Lisa Nelson shared, "We've been working tirelessly to create products that not only meet the needs of health-conscious individuals but exceed them. Our partnership with the U.S. Armed Forces is a testament to the strength and effectiveness of our mushroom supplement. It's a game-changer for CBD Life Sciences, and we are incredibly excited for the opportunities it opens for our company, shareholders, and future investors."
As CBD Life Sciences continues to expand its product line and strategic partnerships, it offers its shareholders a unique opportunity to be part of something transformative. This MOU will likely serve as a major growth catalyst, not only driving the company's revenue but also elevating its brand into new, high-profile markets.
Why Investors Should Pay Attention
CBD Life Sciences is on the cusp of breaking through to new levels of growth and profitability. With the company's proven track record of success, this MOU signals a major step forward, making CBDL a strong contender in the health and wellness industry. Current shareholders can anticipate sustained momentum, while prospective investors have a rare opportunity to jump in as the company embarks on this monumental new phase.
The signing of this MOU represents more than just a business deal-it's a declaration of intent. CBD Life Sciences is committed to advancing its mission of delivering world-class health products while delivering unparalleled value to its investors. In a market flooded with health fads and trends, CBDL is setting itself apart with science-backed, high-demand products that address real needs in both military and civilian populations.
Looking Ahead: A Future of Endless Possibility
As CBD Life Sciences builds on the foundation laid by its record-breaking revenue growth, the company is strategically positioned to push boundaries, explore new markets, and deliver products that redefine health and wellness. Investors who recognize the potential for growth in the adaptogens space are in a prime position to capitalize on the rapid evolution of CBDL's brand and reach.
About CBD Life Sciences, Inc.
CBD Life Sciences, Inc. (CBDL) is a forward-thinking, vertically integrated CBD company that specializes in the creation of high-quality CBD-based and nutraceutical products. The company's commitment to innovation and natural solutions is driving its growth and positioning it as a leader in the health and wellness sector.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What is the significance of CBD Life Sciences' (CBDL) recent MOU with the U.S. Armed Forces?
What is the main product CBDL is offering in relation to the MOU with the U.S. Armed Forces?
How much has CBDL's revenue increased since February 2024?
What is the projected size of the global adaptogens market by 2028?
